Overview

Fenretinide in Treating Patients With Leukoplakia of the Mouth

Status:
Completed
Trial end date:
2004-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development of or treat early cancer. Fenretinide may be an effective drug in treating leukoplakia. PURPOSE: Randomized phase II trial to study the effectiveness of fenretinide in treating patients who have leukoplakia of the mouth.
Phase:
Phase 2
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
National Cancer Institute (NCI)
Treatments:
Fenretinide